Networking the healthcare world through Content, Events and Connections

WHF Magazine Globe

BioNTech expects Omicron-adapted vaccine deliveries as soon as October

August 9, 2022
by Healthcare World

New omicron specific vaccines are expected to be ready in the coming months, say vaccine producers

With 3.6 billion doses already shipped globally, current demand for the vaccine in Europe and the US is waning, as many people in these regions have already received three or four doses.

However, booster campaigns using upgraded shots specifically targeting the Omicron variant are expected to increase demand in autumn. Pending regulatory approval, BioNTech has stated that both its adapted vaccines will be available in time for these booster campaigns.

BioNTech and Pfizer submitted one of the adapted vaccines, which targets the BA.1 subvariant, to the EU drugs regulator EMA last month, with delivery pending approval.

The other, targeting the BA.4 and BA.5 subvariants as recommended by the U.S. drug regulator, will begin clinical trials this month with initial doses expected to be shipped from as early as October.

The company also reaffirmed its 2022 vaccine revenue guidance of 13 to 17 billion euros, down from 19 billion last year. Pfizer, BioNTech’s vaccine partner, forecasts $32 billion in full-year COVID-19 vaccine sales.

“With our strong performance year to date, we believe to be well on track to achieve our previous financial guidance for the ongoing financial year,” said Jens Holstein, Chief Financial Officer of BioNTech.

The company acknowledged some uncertainty about the impact of the current natural gas shortage, which it uses for the commercial production of its COVID-19 vaccine, would mean for operations – but said that it did not expect to be affected by the current shortage and is putting measures in place to mitigate risk.

Report courtesy of Reuters

Share this article

< Back to home
Share This